#USA #Dublin #Alkermes #Narcolepsy #Alxorexton

Alkermes Releases Positive Topline Results from Vibrance-2 Study

Alkermes plc, a company focused on innovative neuroscience treatment, has recently announced promising topline results from its Vibrance-2 study evaluating Alixorexton, a unique oral medication for patients with Narcolepsy Type 2 (NT2). This groundbreaking research highlights Alixorexton as the first oral orexin 2 receptor agonist to demonstrate efficacy in a substantial Phase 2 study. With dual primary endpoints met, the study showcased significant enhancements in both wakefulness and a reduction in excessive daytime sleepiness when compared to placebos.

In the Vibrance-2 study, which included 93 participants, patients were randomly assigned to receive once-daily doses of Alixorexton in varying strengths (10 mg, 14 mg, or 18 mg) or a placebo over an eight-week period. Remarkably, the results indicated clinically meaningful improvements in sleep latency on the Maintenance of Wakefulness Test (MWT) and a noteworthy reduction in daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS). The data indicates that these improvements were statistically significant, especially for the 14 mg and 18 mg doses, marking a pivotal moment for narcolepsy treatment options.

Important Findings from the Study

The Vibrance-2 trial has highlighted the importance of Alixorexton in managing NT2, a chronic neurological sleep disorder primarily characterized by significant daytime sleepiness. Interestingly, patients in this group tend to display varied symptoms and responses to treatment. Unlike Narcolepsy Type 1 (NT1), where orexin deficiency is well-established, NT2 presents a more nuanced understanding of its underlying causes, often associated with normal orexin levels.

The Vibrance-2 investigation places Alixorexton in a spotlight as a potential treatment alternative, garnering attention from experts in the field. Dr. Emmanuel Mignot from Stanford University expressed enthusiasm over the study's results, emphasizing that the data indicates a groundbreaking solution to improve the wakefulness of patients suffering from NT2, which has been a long-standing challenge in clinical science.

Despite the encouraging news surrounding the efficacy of Alixorexton, safety monitoring has remained a priority. The drug was reported to be well-tolerated in all doses tested throughout the study's duration, with a majority of treatment-related adverse events being mild to moderate in severity. The most frequently reported issues included dizziness and insomnia. Importantly, there were no serious adverse events logged during the trial, highlighting Alixorexton's safety profile as a priority alongside its efficacy.

Looking Ahead: The Future of Alixorexton

Alkermes plans to present detailed results, including patient-reported outcomes focused on cognition and fatigue, at an upcoming scientific meeting. The company also plans to move toward a global Phase 3 program for Alixorexton, anticipated to begin in early 2026.

The excitement surrounding the results of Vibrance-2 exemplifies a significant milestone in chronic sleep disorder treatment for Narcolepsy Type 2. Craig Hopkinson, Alkermes’ Chief Medical Officer, reiterated the potential of Alixorexton to transform treatment standards and elucidated the importance of furthering research to ensure that patients receive optimal care moving forward.

In summary, the Vibrance-2 Phase 2 study's results denote an exciting advancement in our understanding of NT2 and provide hope for improving the lives of those affected. With plans in place for Phase 3 trials, the outlook for Alixorexton appears bright as the company aims to bring a new treatment option into the market for narcolepsy patients worldwide.